Judge Takes CMS HEMP-MARIJUANA CBD Program Under Advisement - As Evidence Mounts That Medicare May Be Moving Ahead of FDA Science
In SAM et al. v. Kennedy (1:26-cv-01081), the Court Weighs Whether CMS Overstepped Its Authority by allowing Hemp, Marijuana Cannabinoid Access Without FDA Approval.
Duane Boise, CEO of MMJ International Holdings stated "By holding the motion under advisement rather than ruling immediately, the court signaled that the issue is both complex and consequential."
WASHINGTON, May 8, 2026 (Newswire.com) - The future of federal cannabinoid policy now sits with the court after Judge Trevor N. McFadden took under advisement an emergency motion to halt the Centers for Medicare & Medicaid Services' (CMS) cannabinoid access program.
The case,
Smart Approaches to Marijuana (SAM), et al. v. Robert F. Kennedy Jr., et al.
Case No. 1:26-cv-01081 (D.D.C.),
challenges whether CMS exceeded its authority by allowing provider mediated furnishing of certain cannabinoid products to Medicare beneficiaries without approval from the U.S. Food and Drug Administration.
A Decision With National Implications
At issue is not just one program-but a fundamental question:
For decades, the answer has been no.
The established federal sequence has been:
clinical research - clinical trials - FDA approval - patient access
The CMS Beneficiary Engagement Incentive (BEI) model reverses that order.
The Court Signals the Stakes
By holding the motion under advisement rather than ruling immediately, the court signaled that the issue is both complex and consequential.
Legal analysts note that such decisions typically involve:
statutory authority limits
separation between CMS and FDA roles
the evidentiary threshold for patient safety
Why This Matters for Patients
The debate is not abstract.
It affects real people-particularly seniors relying on Medicare.
Key concerns raised in the litigation include:
lack of FDA approval for cannabinoid products being furnished
absence of standardized dosing and manufacturing controls
limited long-term safety data
potential exposure of vulnerable populations to unvalidated therapies
The Impact on Scientific Development
Clinical-stage developers pursuing cannabinoid therapies through FDA pathways warn that reimbursement-first models may undermine the incentive to conduct rigorous trials.
Companies investing in:
Investigational New Drug (IND) programs
stability and formulation testing
safety and toxicology studies
face a growing concern:
If access comes before evidence, the incentive to generate evidence weakens.
CMS Authority Under Scrutiny
The Centers for Medicare & Medicaid Services Innovation Center has broad authority to test payment and care delivery models.
However, the lawsuit argues that this authority does not extend to redefining what qualifies as a therapeutic product eligible for Medicare-connected use.
That role has historically belonged to the FDA.
What Happens Next
The court is expected to issue a written ruling in the coming days, determining whether the CMS program:
proceeds as implemented
is partially restricted
or is halted pending further litigation
In Closing
The outcome of this case will help define the future of cannabinoid medicine in the United States.
At its core, the issue is simple:
Should medicine follow science-
or should access come first, and evidence later?
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
Source: MMJ International Holdings
Share:
Tags: administrative law CMS authority challenge, administrative procedure act CMS violation, biotech cannabis companies United States, biotech regulatory risk cannabinoids, Boston biotech cannabis research, California cannabis regulation federal conflict, cannabinoid clinical trials United States, cannabinoid drug approval pathway, cannabinoid drug development investment, cannabinoid litigation United States, cannabinoid medicine FDA pathway, cannabis pharmaceutical companies USA, cannabis policy lawsuit US, cannabis regulation conflict USA, cannabis stocks federal policy impact, CBD in Medicare programs, CBD Medicare reimbursement issue, CBD regulation investment risk USA, Chicago healthcare law cannabis, clinical trial requirements cannabinoids, CMS BEI program lawsuit, CMS beneficiary engagement incentive program, CMS cannabinoid policy, CMS Innovation Center authority, CMS Innovation Center legal authority, CMS Medicare CBD debate, CMS Medicare innovation model cannabinoids, CMS Medicare pilot program cannabinoids, CMS policy impact healthcare investors, CMS vs FDA battle, FDA approval cannabis medicine, FDA approval impact cannabis stocks, FDA botanical drug development cannabis, FDA bypass controversy, FDA drug approval vs CMS policy, FDA vs CMS regulatory conflict, federal agency overreach CMS FDA conflict, federal cannabis policy United States, federal cannabis reform impact markets, federal court CBD ruling, federal healthcare litigation Washington DC, federal healthcare policy cannabinoids, federal healthcare reimbursement cannabinoids, federal injunction CMS BEI, Florida cannabis investors policy news, government CBD program lawsuit, healthcare policy risk cannabis sector, healthcare policy scandal cannabinoids, healthcare policy seniors United States, hemp CBD federal policy dispute, Huntington’s disease cannabis treatment research, IND cannabis drug development, Los Angeles cannabis policy federal case, Medicare cannabinoid access lawsuit, Medicare cannabinoid coverage policy, Medicare CBD controversy, Medicare CBD program controversy, Medicare drug approval standards USA, Medicare experimental treatment controversy, Medicare patient safety CBD, Medicare policy federal court case, MMJ BioPharma clinical trials cannabis, New York healthcare policy CBD, orphan drug designation cannabinoids, pharmaceutical cannabis market USA, pharmaceutical cannabis regulation USA, preliminary injunction cannabis policy case, RFK Jr CMS lawsuit cannabinoids, Rhode Island biotech cannabis development, SAM Smart Approaches to Marijuana lawsuit, SAM v Kennedy case 1:26-cv-01081, senior healthcare cannabinoid risk, seniors CBD Medicare risk, Tampa Florida healthcare policy news, Texas cannabis legal policy update, Trevor McFadden CMS ruling, U.S. District Court District of Columbia cannabis case, unapproved CBD products Medicare, United States federal court cannabis case, US healthcare policy cannabinoids, US Medicare CBD controversy, Washington DC cannabis policy
